New pharmacological perspectives and therapeutic potential of PPAR-γ agonists : Endocrine and metabolic agents
- Author
- ALARCON DE LA LASTRA, C1 ; SANCHEZ-FIDALGO, S1 ; VILLEGAS, I1 ; MOTILVA, V1
[1] Departamento de Farmacología, Facultad de Farmacia, Universidad de Sevilla, Spain - Source
Current pharmaceutical design. 2004, Vol 10, Num 28, pp 3505-3524, 20 p ; ref : 200 ref
- ISSN
- 1381-6128
- Scientific domain
- Pharmacology drugs
- Publisher
- Bentham Science, Hilversum
- Publication country
- Netherlands
- Document type
- Article
- Language
- English
- Keyword (fr)
- Activité biologique Agoniste Article synthèse Inflammation Perspective Physiopathologie Recherche développement Récepteur PPAR-γ Thiazolidinedione dérivé Traitement
- Keyword (en)
- Biological activity Agonist Review Inflammation Perspective Pathophysiology Research and development PPAR-γ receptor Thiazolidinedione derivatives Treatment
- Keyword (es)
- Actividad biológica Agonista Artículo síntesis Inflamación Perspectiva Fisiopatología Investigación desarrollo Receptor PPAR-γ Tiazolidinediona derivado Tratamiento
- Classification
- Pascal
- 002 Biological and medical sciences / 002B Medical sciences / 002B02 Pharmacology. Drug treatments / 002B02L Bones, joints and connective tissue. Antiinflammatory agents
- Discipline
- Pharmacological treatments
- Origin
- Inist-CNRS
- Database
- PASCAL
- INIST identifier
- 16206114
Sauf mention contraire ci-dessus, le contenu de cette notice bibliographique peut être utilisé dans le cadre d’une licence CC BY 4.0 Inist-CNRS / Unless otherwise stated above, the content of this bibliographic record may be used under a CC BY 4.0 licence by Inist-CNRS / A menos que se haya señalado antes, el contenido de este registro bibliográfico puede ser utilizado al amparo de una licencia CC BY 4.0 Inist-CNRS
Access to the document
Install on your browser
DOI
10.2174/1381612043382909 
https://dx.doi.org/10.2174/1381612043382909
"O:13:\"PanistOpenUrl\":36:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000idc\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:24:\"10.2174\/1381612043382909\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:111:\"New pharmacological perspectives and therapeutic potential of PPAR-\u03b3 agonists : Endocrine and metabolic agents\";s:9:\"\u0000*\u0000jtitle\";s:29:\"Current pharmaceutical design\";s:9:\"\u0000*\u0000stitle\";s:16:\"Curr. pharm. des\";s:7:\"\u0000*\u0000date\";s:4:\"2004\";s:9:\"\u0000*\u0000volume\";s:2:\"10\";s:8:\"\u0000*\u0000issue\";s:2:\"28\";s:8:\"\u0000*\u0000spage\";s:4:\"3505\";s:8:\"\u0000*\u0000epage\";s:4:\"3524\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"1381-6128\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:20:\"ALARCON DE LA LASTRA\";s:10:\"\u0000*\u0000aufirst\";s:1:\"C\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:3:{i:0;s:18:\"SANCHEZ-FIDALGO, S\";i:1;s:11:\"VILLEGAS, I\";i:2;s:10:\"MOTILVA, V\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:111:\"New pharmacological perspectives and therapeutic potential of PPAR-\u03b3 agonists : Endocrine and metabolic agents\";s:8:\"\u0000*\u0000place\";s:9:\"Hilversum\";s:6:\"\u0000*\u0000pub\";s:15:\"Bentham Science\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:2:\"20\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Panist access
"O:12:\"IstexOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:24:\"10.2174\/1381612043382909\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:111:\"New pharmacological perspectives and therapeutic potential of PPAR-\u03b3 agonists : Endocrine and metabolic agents\";s:9:\"\u0000*\u0000jtitle\";s:29:\"Current pharmaceutical design\";s:9:\"\u0000*\u0000stitle\";s:16:\"Curr. pharm. des\";s:7:\"\u0000*\u0000date\";s:4:\"2004\";s:9:\"\u0000*\u0000volume\";s:2:\"10\";s:8:\"\u0000*\u0000issue\";s:2:\"28\";s:8:\"\u0000*\u0000spage\";s:4:\"3505\";s:8:\"\u0000*\u0000epage\";s:4:\"3524\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"1381-6128\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:20:\"ALARCON DE LA LASTRA\";s:10:\"\u0000*\u0000aufirst\";s:1:\"C\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:3:{i:0;s:18:\"SANCHEZ-FIDALGO, S\";i:1;s:11:\"VILLEGAS, I\";i:2;s:10:\"MOTILVA, V\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:111:\"New pharmacological perspectives and therapeutic potential of PPAR-\u03b3 agonists : Endocrine and metabolic agents\";s:8:\"\u0000*\u0000place\";s:9:\"Hilversum\";s:6:\"\u0000*\u0000pub\";s:15:\"Bentham Science\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:2:\"20\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Istex access
"O:16:\"UnpaywallOpenUrl\":35:{s:8:\"\u0000*\u0000email\";s:27:\"assistance-portail@inist.fr\";s:6:\"\u0000*\u0000fmt\";N;s:6:\"\u0000*\u0000doi\";s:24:\"10.2174\/1381612043382909\";s:6:\"\u0000*\u0000pii\";N;s:7:\"\u0000*\u0000pmid\";N;s:9:\"\u0000*\u0000atitle\";N;s:9:\"\u0000*\u0000jtitle\";N;s:9:\"\u0000*\u0000stitle\";N;s:7:\"\u0000*\u0000date\";N;s:9:\"\u0000*\u0000volume\";N;s:8:\"\u0000*\u0000issue\";N;s:8:\"\u0000*\u0000spage\";N;s:8:\"\u0000*\u0000epage\";N;s:8:\"\u0000*\u0000pages\";N;s:7:\"\u0000*\u0000issn\";N;s:8:\"\u0000*\u0000eissn\";N;s:9:\"\u0000*\u0000aulast\";N;s:10:\"\u0000*\u0000aufirst\";N;s:9:\"\u0000*\u0000auinit\";N;s:10:\"\u0000*\u0000auinitm\";N;s:5:\"\u0000*\u0000au\";N;s:9:\"\u0000*\u0000aucorp\";N;s:7:\"\u0000*\u0000isbn\";N;s:8:\"\u0000*\u0000coden\";N;s:8:\"\u0000*\u0000genre\";N;s:7:\"\u0000*\u0000part\";N;s:9:\"\u0000*\u0000btitle\";N;s:8:\"\u0000*\u0000title\";N;s:8:\"\u0000*\u0000place\";N;s:6:\"\u0000*\u0000pub\";N;s:10:\"\u0000*\u0000edition\";N;s:9:\"\u0000*\u0000tpages\";N;s:9:\"\u0000*\u0000series\";N;s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";N;}"
Unpaywall access
"O:16:\"EuropePMCOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:24:\"10.2174\/1381612043382909\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:111:\"New pharmacological perspectives and therapeutic potential of PPAR-\u03b3 agonists : Endocrine and metabolic agents\";s:9:\"\u0000*\u0000jtitle\";s:29:\"Current pharmaceutical design\";s:9:\"\u0000*\u0000stitle\";s:16:\"Curr. pharm. des\";s:7:\"\u0000*\u0000date\";s:4:\"2004\";s:9:\"\u0000*\u0000volume\";s:2:\"10\";s:8:\"\u0000*\u0000issue\";s:2:\"28\";s:8:\"\u0000*\u0000spage\";s:4:\"3505\";s:8:\"\u0000*\u0000epage\";s:4:\"3524\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"1381-6128\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:20:\"ALARCON DE LA LASTRA\";s:10:\"\u0000*\u0000aufirst\";s:1:\"C\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:3:{i:0;s:18:\"SANCHEZ-FIDALGO, S\";i:1;s:11:\"VILLEGAS, I\";i:2;s:10:\"MOTILVA, V\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:111:\"New pharmacological perspectives and therapeutic potential of PPAR-\u03b3 agonists : Endocrine and metabolic agents\";s:8:\"\u0000*\u0000place\";s:9:\"Hilversum\";s:6:\"\u0000*\u0000pub\";s:15:\"Bentham Science\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:2:\"20\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Europe PubMed Central access
"O:11:\"BaseOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:24:\"10.2174\/1381612043382909\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:111:\"New pharmacological perspectives and therapeutic potential of PPAR-\u03b3 agonists : Endocrine and metabolic agents\";s:9:\"\u0000*\u0000jtitle\";s:29:\"Current pharmaceutical design\";s:9:\"\u0000*\u0000stitle\";s:16:\"Curr. pharm. des\";s:7:\"\u0000*\u0000date\";s:4:\"2004\";s:9:\"\u0000*\u0000volume\";s:2:\"10\";s:8:\"\u0000*\u0000issue\";s:2:\"28\";s:8:\"\u0000*\u0000spage\";s:4:\"3505\";s:8:\"\u0000*\u0000epage\";s:4:\"3524\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"1381-6128\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:20:\"ALARCON DE LA LASTRA\";s:10:\"\u0000*\u0000aufirst\";s:1:\"C\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:3:{i:0;s:18:\"SANCHEZ-FIDALGO, S\";i:1;s:11:\"VILLEGAS, I\";i:2;s:10:\"MOTILVA, V\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:111:\"New pharmacological perspectives and therapeutic potential of PPAR-\u03b3 agonists : Endocrine and metabolic agents\";s:8:\"\u0000*\u0000place\";s:9:\"Hilversum\";s:6:\"\u0000*\u0000pub\";s:15:\"Bentham Science\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:2:\"20\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Base Search access
"O:12:\"ArXivOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:24:\"10.2174\/1381612043382909\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:111:\"New pharmacological perspectives and therapeutic potential of PPAR-\u03b3 agonists : Endocrine and metabolic agents\";s:9:\"\u0000*\u0000jtitle\";s:29:\"Current pharmaceutical design\";s:9:\"\u0000*\u0000stitle\";s:16:\"Curr. pharm. des\";s:7:\"\u0000*\u0000date\";s:4:\"2004\";s:9:\"\u0000*\u0000volume\";s:2:\"10\";s:8:\"\u0000*\u0000issue\";s:2:\"28\";s:8:\"\u0000*\u0000spage\";s:4:\"3505\";s:8:\"\u0000*\u0000epage\";s:4:\"3524\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"1381-6128\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:20:\"ALARCON DE LA LASTRA\";s:10:\"\u0000*\u0000aufirst\";s:1:\"C\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:3:{i:0;s:18:\"SANCHEZ-FIDALGO, S\";i:1;s:11:\"VILLEGAS, I\";i:2;s:10:\"MOTILVA, V\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:111:\"New pharmacological perspectives and therapeutic potential of PPAR-\u03b3 agonists : Endocrine and metabolic agents\";s:8:\"\u0000*\u0000place\";s:9:\"Hilversum\";s:6:\"\u0000*\u0000pub\";s:15:\"Bentham Science\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:2:\"20\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
arXiv access
